Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2017

View Archived Issues

GSK reflects on accomplishments of second quarter 2017

Takeda presents key events of first quarter of fiscal 2017

Exposure to MeNZB vaccine associated with reduced rates of gonorrhea diagnosis

First-in-human results for personalized RNA mutanome vaccine IVAC MUTANOME

FDA grants priority review to RBP-6000 NDA, clearance for buprenorphine assay

Kite Pharma submits MAA to EMA for axicabtagene ciloleucel

PellePharm announces topline phase II data for topical patidegib in Gorlin syndrome

Syndros, the first and only FDA-approved liquid dronabinol, becomes available by prescription

BLU-667, a RET inhibitor, shows promise for RET-driven thyroid cancer

Antigen Express and Merck & Co. agree to test AE-37 with Keytruda in triple-negative breast cancer

BLA submission for trastuzumab biosimilar ABP-980

Isogenica licenses antibody libraries to Takeda

FDA grants orphan drug designation to RA-101495 for PNH

Bayer discloses soluble guanylate cyclase activators

Aerie collaborates with DSM on technology to deliver compounds for retinal diseases

FDA accepts for review BLA for trastuzumab biosimilar CT-P6

Chemerin receptor antagonists presented by Shenzhen Institute of Advanced Technology

Celgene details pipeline developments of second quarter 2017

Recro submits NDA for intravenous meloxicam for postoperative pain

Phase III MAP US study of RHB-104 in Crohn's disease cleared to continue

New tau PET ligands [18F]AM-PBB3 and [18F]PM-PBB3 evaluated in humans

Bristol-Myers Squibb and Clovis sign clinical collaboration agreement to test Opdivo with Rubraca

FDA clears IND for phase I study of PTI-125 for Alzheimer's disease

Intercept reports results from trials of obeticholic acid in PSC and NASH

Emergent BioSolutions' development of auto-injector for nerve agent antidote gets financial support

Kitov announces NDA submission for KIT-302

Loxo to acquire Redx's BTK inhibitor program

FDA awards breakthrough therapy designation to acalabrutinib for mantle cell lymphoma

Lumosa initiates phase I trial of LT-3001 for acute ischemic stroke

Nerlynx launched in U.S.

Astellas seeks Japanese approval for fidaxomicin for infectious enteritis caused by C. difficile

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...